Bariatric surgery — often referred to simply as obesity surgery — encompasses a group of operations designed to support long-term weight control and improvement of obesity-related metabolic disease in individuals living with severe (morbid) obesity. This page reviews the physiological rationale behind bariatric procedures, the surgical techniques in current use, the effect of metabolic surgery on insulin resistance, postoperative nutrition, how success is measured, the risk of weight regain, and the criteria used to select suitable candidates — all in light of current international guidelines. The underlying premise is that obesity is a multidimensional chronic disease; surgery therefore has a defined role, clear limits, and potential complications that deserve honest discussion. The topic is presented from the perspective of the General Surgery department at Koru Hospital in Ankara, reflecting established clinical practice, and may be of particular interest to international patients considering treatment in Turkey.
What Is Bariatric (Obesity) Surgery? How Do the Operation and the Overall Process Work?
Bariatric surgery is the collective term for operations that modify the anatomy of the stomach and/or small intestine in patients diagnosed with morbid obesity, with the goal of achieving durable weight loss and improving obesity-related metabolic conditions. Because obesity is characterised by chronic energy imbalance, hormonal dysregulation, and central fat accumulation, these procedures are regarded not merely as weight-reducing operations but as metabolic interventions that can contribute to the management of type 2 diabetes, hypertension, dyslipidaemia, and obstructive sleep apnoea. According to the 2022 update of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and the guidelines of the American Society for Metabolic and Bariatric Surgery (ASMBS), surgery may be considered in individuals with a body mass index (BMI) above 35 kg/m² even in the absence of additional comorbidities.
Surgical techniques are broadly classified as restrictive, malabsorptive, or hybrid. Restrictive procedures reduce stomach volume to produce early satiety; malabsorptive procedures limit nutrient absorption in the small intestine; hybrid procedures combine both mechanisms. The vast majority of operations today are performed using minimally invasive laparoscopic or robotic approaches, which shorten wound-healing time and reduce postoperative pain. Depending on the technique, operating time typically ranges from 60 to 180 minutes, and the hospital stay in uncomplicated cases is usually 2 to 4 days.
The pathway begins with a multidisciplinary assessment involving endocrinology, nutrition, psychiatry, and pulmonology. Preoperative work-up includes upper gastrointestinal endoscopy, Helicobacter pylori screening, thyroid function tests, HbA1c measurement, and cardiopulmonary risk evaluation. A low-calorie liquid diet for two to four weeks before surgery reduces liver volume and improves the laparoscopic view. After the operation, care centres on early mobilisation, venous thromboembolism prophylaxis with low-molecular-weight heparin, a staged nutrition plan, and a structured long-term follow-up programme. Review visits are scheduled at one week, one month, three months, six months, and twelve months after surgery, with annual follow-up thereafter. In this sense, the operation is not an isolated intervention but the starting point of a lifelong metabolic management programme.
What Does Bariatric Surgery Actually Mean? The Physiology Behind the Surgical Approach to Obesity
Bariatric surgery is more than mechanically making the stomach smaller: it is a physiological intervention that reorganises the neuroendocrine signalling network of the gastrointestinal tract. After surgery, the secretion patterns of appetite- and satiety-related hormones — ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), oxyntomodulin, and cholecystokinin — change markedly. In techniques that resect the gastric fundus, levels of ghrelin, often called the hunger hormone, fall; in procedures where nutrients reach the distal small bowel earlier, the incretin response is amplified. These changes contribute to a reduction in insulin resistance and improved glycaemic control.
Two complementary hypotheses describe this physiology. The foregut hypothesis proposes that excluding the duodenum from the passage of food reduces the release of anti-incretin factors that promote insulin resistance. The hindgut hypothesis holds that the early arrival of nutrients in the distal ileum stimulates GLP-1 and PYY secretion, helping preserve beta-cell function and prolonging satiety. Taken together, these mechanisms show that surgery works not only through calorie restriction but through a genuine metabolic reprogramming. Current recommendations of the American Diabetes Association (ADA, 2023) and the European Association for the Study of Diabetes (EASD) reflect this physiological framework.
The effects of surgery are also observed at the level of energy expenditure, the gut microbiota, bile acid cycling, and the central nervous system. Following bariatric procedures, the size and composition of the bile acid pool change, and glucose and lipid metabolism are remodelled via the FXR and TGR5 receptor pathways. Shifts in the gut microbiota favouring Bacteroidetes have been reported, together with increased production of short-chain fatty acids. These microbial changes strengthen the intestinal barrier and contribute to lower levels of systemic low-grade inflammation markers such as CRP and IL-6. Partial restoration of leptin sensitivity in hypothalamic appetite centres also reshapes the food reward system: functional MRI studies show reduced reward-centre activation in response to high-calorie foods after surgery. The operation is therefore best understood not as an isolated gastrointestinal procedure but as a multi-organ metabolic recalibration.
Which Bariatric Techniques Are Most Commonly Performed?
The techniques most frequently performed in current clinical practice are laparoscopic sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), one-anastomosis gastric bypass (OAGB/MGB), and biliopancreatic diversion with duodenal switch (BPD/DS). According to IFSO global data from 2022, sleeve gastrectomy accounts for roughly half of all bariatric procedures worldwide, while Roux-en-Y gastric bypass represents about thirty percent. The one-anastomosis bypass has seen a marked rise in use over the past decade. BPD/DS is reserved for a limited group of patients with advanced obesity and severe metabolic disturbance.
In sleeve gastrectomy, approximately eighty percent of the stomach is removed along the greater curvature, creating a tubular stomach; reported excess weight loss (%EWL) at five years averages between fifty-five and seventy percent. In Roux-en-Y gastric bypass, a gastric pouch of roughly 30 ml is created and the small intestine is anastomosed about 100–150 cm downstream; five-year %EWL is reported between sixty and eighty percent, with type 2 diabetes remission rates reaching sixty to eighty percent. In OAGB, a long, narrow gastric pouch is joined to the bowel with a single anastomosis and a biliopancreatic limb of 150–200 cm, balancing restriction and malabsorption.
Choice of technique takes into account age, BMI, comorbidity burden, the presence of gastro-oesophageal reflux, gastric anatomy, eating habits, and the patient's capacity to adhere to follow-up. In patients with pronounced reflux, Roux-en-Y gastric bypass is generally preferred; in very high BMI and treatment-resistant type 2 diabetes, BPD/DS or SADI-S come to the fore. Decisions in adolescents and in older adults are individualised. Bypass procedures tend to suit patients with a strong preference for carbohydrates, whereas restrictive procedures may be more appropriate for those able to control solid-food portions. Sleeve gastrectomy is avoided when Barrett's oesophagus is present, in which case gastric bypass is preferred; if a hiatal hernia coexists, repair during the same operation is recommended. With the wider adoption of robotic surgery, three-dimensional visualisation and high-precision instruments offer advantages particularly in complex revisional cases. There is, in short, no single technique that suits everyone — the decision is made case by case.
What Are Diabetes Surgery and Metabolic Surgery? How Is Insulin Resistance Addressed Surgically?
Metabolic surgery describes the use of bariatric procedures not only for weight loss but for the management of metabolic disorders such as type 2 diabetes, dyslipidaemia, non-alcoholic fatty liver disease, and polycystic ovary syndrome. Often called diabetes surgery, this approach is recommended in current guidelines particularly for patients with type 2 diabetes and a BMI of 30–34.9 kg/m² whose disease responds inadequately to medical therapy. The consensus report of the Second Diabetes Surgery Summit (DSS-II) and the ADA 2023 Standards of Care position metabolic surgery as an evidence-based option within diabetes management.
The surgical effect on insulin resistance begins with early hormonal changes that are independent of weight loss. From the first postoperative days, the postprandial GLP-1 response increases, beta-cell insulin secretion improves, and hepatic insulin sensitivity rises appreciably — leading to lower fasting glucose before significant weight loss has occurred. Over the longer term, glycaemic control is maintained through reduced adipose tissue mass, regression of low-grade inflammation, and improved muscle insulin sensitivity. Reported five-year remission rates for type 2 diabetes range from sixty to eighty percent after RYGB and forty-five to sixty percent after sleeve gastrectomy, with a partial decline observed at ten-year follow-up.
The decision for metabolic surgery weighs diabetes duration, current antidiabetic medication, C-peptide level, HbA1c, the presence of microvascular and macrovascular complications, and the patient's ability to adhere to follow-up. Remission is considerably more likely when diabetes has been present for fewer than eight years, C-peptide is preserved, and the patient uses no insulin or only a low dose. Validated risk-scoring systems such as DiaRem, Ad-DiaRem, and ABCD help estimate the probability of remission before surgery. After the operation, patients are monitored for hypoglycaemia, dumping syndrome, and reactive hyperinsulinaemic hypoglycaemia, and antidiabetic doses are tapered stepwise. Sulfonylureas are usually discontinued early because of hypoglycaemia risk, while metformin may be continued postoperatively when needed. Metabolic surgery is thus regarded as a complementary component within the multi-modal management of type 2 diabetes.
How Should You Eat After Bariatric Surgery? Progressing from Liquids to Solid Food
Postoperative nutrition follows a staged protocol designed to protect the healing anastomosis, sustain weight loss, and prevent micronutrient deficiency. The first stage — clear liquids — covers weeks 0 to 2 and consists of unsweetened tea, strained broth, and diluted fruit juice. Full liquids and puréed foods follow in weeks 2 to 4, including milk, yoghurt and yoghurt-based drinks, soups, and puréed vegetables. A soft-solid phase begins in weeks 4 to 6, featuring easily chewed foods such as steamed vegetables, dishes made with minced meat, and fish. From the end of the second month, patients transition gradually to a normal solid diet.
Daily protein intake is ideally kept at 60–80 grams, supplemented with whey protein when necessary. Fluid intake is planned at a minimum of 1.5–2 litres per day, but liquids are taken between meals rather than with them. Refined sugar, carbonated drinks, alcohol, and high-fat processed foods are restricted because of the risk of dumping syndrome and weight regain. Meals are small and frequent — five to six per day — eaten slowly and chewed thoroughly, a routine that also protects the newly created gastric pouch mechanically.
Micronutrient supplementation continues lifelong regardless of the procedure performed. Recommended supplements include a daily multivitamin, vitamin B12 (oral or intramuscular), vitamin D, calcium citrate (1,200–1,500 mg/day), iron, folic acid, zinc, magnesium, and thiamine; after malabsorptive procedures, the fat-soluble vitamins A, D, E, and K are added. Annual monitoring covers full blood count, ferritin, B12, folate, 25-OH vitamin D, calcium, PTH, zinc, and copper. Women planning pregnancy are advised to wait at least 12–18 months after surgery and to use effective contraception during this period. Nutrition, in other words, is not an afterthought but an inseparable component of the surgical treatment itself.
How Is Success Measured After Bariatric Surgery? What Are the Risks and Safety Principles?
Success is judged not by the number of kilograms lost alone but by improvement of comorbidities, gains in quality of life, and the management of complications. The classic benchmark has been loss of more than fifty percent of excess weight (%EWL > 50), although current guidelines favour percentage of total weight loss (%TWL) as a more reliable measure. At five years, average %TWL is reported at around twenty-five to thirty percent for RYGB and twenty to twenty-five percent for sleeve gastrectomy. Remission rates for type 2 diabetes, hypertension, and obstructive sleep apnoea are integral parts of the overall assessment.
Risks are grouped into early and late complications. In the early period, anastomotic or staple-line leak is reported at one to three percent, bleeding at one to two percent, and venous thromboembolism at around one percent. Perioperative mortality in experienced centres is in the range of 0.1–0.3 percent, and the overall major complication rate is approximately five percent. Portal vein thrombosis is observed in under one percent of cases, particularly after sleeve gastrectomy, and is managed with early diagnosis and anticoagulation. Late complications include stricture (one to two percent), marginal ulcer after bypass (five to ten percent), internal hernia (one to three percent), and gallstones (ten to thirty percent). New-onset gastro-oesophageal reflux and Barrett's oesophagus, particularly after sleeve gastrectomy, are conditions that require extended follow-up.
Safety rests on surgery being performed in an experienced centre, multidisciplinary patient selection, standardised enhanced recovery after surgery (ERAS) protocols, and the combination of low-molecular-weight heparin with mechanical thromboprophylaxis. Centre volumes of at least fifty cases per year have been inversely associated with complication rates. Preoperative smoking cessation, optimisation of HbA1c, CPAP use in obstructive sleep apnoea, and psychosocial evaluation form further links in the safety chain; stopping smoking at least four to six weeks before surgery matters for wound healing and leak risk. After discharge, early mobilisation, staged nutrition, and regular follow-up visits are decisive. Tachycardia, abdominal pain, fever, or shortness of breath within the first thirty days after discharge warrants urgent assessment for leak or embolism. Success, then, is defined not by a single number but within a multidimensional, long-term follow-up framework.
Can Weight Return After Bariatric Surgery? How Is Weight Loss Maintained Over the Long Term?
Weight regain is a recognised and clinically significant issue in long-term follow-up after bariatric surgery. Reported rates vary with technique and length of follow-up: at five years, meaningful regain is described in roughly twenty to thirty percent of patients, and the proportion can rise further at ten years. Clinically, regain is commonly defined as an increase of ten to fifteen percent above the lowest weight achieved. Anatomical contributors include gastric dilatation after sleeve gastrectomy and pouch enlargement or widening of the anastomosis after RYGB.
The causes of regain fall into anatomical, behavioural, psychosocial, and hormonal categories. Behavioural factors include skipping meals, frequent snacking, consumption of high-calorie liquids, carbohydrate-heavy eating, and low physical activity. Psychosocial contributors include emotional eating, binge-eating disorder, depression, and difficulties with stress management. At the hormonal level, ghrelin may partially rise again over time while GLP-1 and PYY responses wane, weakening appetite control. Anatomical causes include a dilated gastric pouch, a wide gastrojejunal anastomosis, and gastro-gastric fistula.
Maintaining weight loss depends on a lifelong lifestyle plan and regular multidisciplinary follow-up. Periodic reviews by a dietitian, psychologist, endocrinologist, and surgeon help preserve macro- and micronutrient balance, detect behavioural risks early, and plan pharmacological support when appropriate. At least 150 minutes of moderate-intensity aerobic exercise per week, plus two to three resistance sessions, is recommended to preserve muscle mass and basal metabolic rate. Newer GLP-1 receptor agonists and dual GIP/GLP-1 agonists — agents such as semaglutide and tirzepatide — are being evaluated as adjunctive pharmacotherapy in postoperative weight regain. Where anatomical causes predominate, revisional surgery may be considered (conversion of sleeve to RYGB or SADI, pouch revision); because revisional procedures carry complication rates two to three times higher than primary operations, such decisions are made in experienced centres after detailed imaging. Long-term outcomes, ultimately, are shaped less on the operating table than in the years of follow-up that come after it.
Who Is a Candidate for Bariatric Surgery? What Scientific Criteria Guide the Decision?
The classical selection criteria, based on the 1991 NIH Consensus Statement, cover individuals with a BMI of 40 kg/m² or above, and those with a BMI of 35–39.9 kg/m² who also have comorbidities such as type 2 diabetes, hypertension, obstructive sleep apnoea, non-alcoholic steatohepatitis, or severe dyslipidaemia. The 2022 IFSO and ASMBS updates have adapted these thresholds: surgery may now be considered at BMI 35 kg/m² and above without requiring comorbidities, while in the BMI 30–34.9 kg/m² range metabolic surgery is positioned as an evidence-based option for treatment-resistant type 2 diabetes and metabolic disease. For Asia-Pacific populations, thresholds are set two points lower to account for ethnic differences in body composition.
The scientific criteria guiding the choice of operation include age, comorbidity profile, presence of gastro-oesophageal reflux, previous abdominal surgery, eating habits, psychosocial circumstances, and pregnancy plans. In adolescents, surgery is considered only when growth is largely complete, BMI is 35 kg/m² or higher with serious comorbidity, family support is well established, and a multidisciplinary team has completed its assessment. In patients over 65, the evaluation focuses on cardiopulmonary reserve, sarcopenia risk, and the expected gain in quality of life. Active alcohol or substance misuse, uncontrolled psychiatric illness, advanced heart failure, cirrhosis, and severe coagulopathy are among the general contraindications.
Preoperative evaluation is a multidisciplinary process involving endocrinology, cardiology, pulmonology, psychiatry, nutrition, and anaesthesia consultations. Upper gastrointestinal endoscopy, Helicobacter pylori screening, thyroid and cortisol assessment, HbA1c, lipid profile, liver function tests, and vitamin D and iron levels are examined routinely; polysomnography is arranged when sleep apnoea is suspected, and echocardiography — with coronary evaluation where indicated — in patients at cardiac risk. Throughout this process, patients receive detailed informed consent covering the surgical options, expected benefits, potential complications, and the need for lifelong follow-up. The final decision reflects the individual's clinical profile and preferences together with the joint assessment of the multidisciplinary team, in line with the approach of the General Surgery department at Koru Hospital in Ankara — a consideration that international patients can discuss in detail during their pre-treatment evaluation.
Please note: The information on this page is provided for general educational purposes and does not replace a medical consultation. Diagnosis and treatment are always planned on an individual basis. If you have symptoms or questions, please consult a qualified physician.
